Literature DB >> 29157365

The Future of Imaging in Detecting Glaucoma Progression.

Fabio Lavinsky1, Gadi Wollstein1, Jenna Tauber1, Joel S Schuman2.   

Abstract

Ocular imaging has been heavily incorporated into glaucoma management and provides important information that aids in the detection of disease progression. Longitudinal studies have shown that the circumpapillary retinal nerve fiber layer is an important parameter for glaucoma progression detection, whereas other studies have demonstrated that macular parameters, such as the ganglion cell inner plexiform layer and optic nerve head parameters, also are useful for progression detection. The introduction of novel technologies with faster scan speeds, wider scanning fields, higher resolution, and improved tissue penetration has enabled the precise quantification of additional key ocular structures, such as the individual retinal layers, optic nerve head, choroid, and lamina cribrosa. Furthermore, extracting functional information from scans such as blood flow rate and oxygen consumption provides new perspectives on the disease and its progression. These novel methods promise improved detection of glaucoma progression and better insight into the mechanisms of progression that will lead to better targeted treatment options to prevent visual damage and blindness.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29157365      PMCID: PMC5777232          DOI: 10.1016/j.ophtha.2017.10.011

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   14.277


  98 in total

Review 1.  Brain changes in glaucoma.

Authors:  N Gupta; Y H Yücel
Journal:  Eur J Ophthalmol       Date:  2003-04       Impact factor: 2.597

2.  Neural losses correlated with visual losses in clinical perimetry.

Authors:  Ronald S Harwerth; Louvenia Carter-Dawson; Earl L Smith; George Barnes; William F Holt; Morris L J Crawford
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

3.  Adaptive-optics ultrahigh-resolution optical coherence tomography.

Authors:  B Hermann; E J Fernández; A Unterhuber; H Sattmann; A F Fercher; W Drexler; P M Prieto; P Artal
Journal:  Opt Lett       Date:  2004-09-15       Impact factor: 3.776

4.  A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity.

Authors:  A T Aman; S Fraser; E A Merritt; C Rodigherio; M Kenny; M Ahn; W G Hol; N A Williams; W I Lencer; T R Hirst
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

5.  Predictive value of colour Doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma.

Authors:  Antonio Martínez; Manuel Sánchez
Journal:  Acta Ophthalmol Scand       Date:  2005-12

Review 6.  A framework for comparing structural and functional measures of glaucomatous damage.

Authors:  Donald C Hood; Randy H Kardon
Journal:  Prog Retin Eye Res       Date:  2007-08-21       Impact factor: 21.198

7.  Optical coherence tomography using a frequency-tunable optical source.

Authors:  S R Chinn; E A Swanson; J G Fujimoto
Journal:  Opt Lett       Date:  1997-03-01       Impact factor: 3.776

8.  Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery.

Authors:  O Zeitz; P Galambos; L Wagenfeld; A Wiermann; P Wlodarsch; R Praga; E T Matthiessen; G Richard; M Klemm
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

Review 9.  Retinotopic organization of primary visual cortex in glaucoma: Comparing fMRI measurements of cortical function with visual field loss.

Authors:  Robert O Duncan; Pamela A Sample; Robert N Weinreb; Christopher Bowd; Linda M Zangwill
Journal:  Prog Retin Eye Res       Date:  2006-11-27       Impact factor: 21.198

10.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

View more
  6 in total

1.  Focal alteration of the intraretinal layers in neurodegenerative disorders.

Authors:  Shriya Airen; Ce Shi; Zhiping Liu; Bonnie E Levin; Joseph F Signorile; Jianhua Wang; Hong Jiang
Journal:  Ann Eye Sci       Date:  2020-03

2.  Attention-Guided 3D-CNN Framework for Glaucoma Detection and Structural-Functional Association Using Volumetric Images.

Authors:  Yasmeen George; Bhavna J Antony; Hiroshi Ishikawa; Gadi Wollstein; Joel S Schuman; Rahil Garnavi
Journal:  IEEE J Biomed Health Inform       Date:  2020-12-04       Impact factor: 5.772

3.  Estimating Visual Field Mean Deviation using Optical Coherence Tomographic Nerve Fiber Layer Measurements in Glaucoma Patients.

Authors:  Ou Tan; David S Greenfield; Brian A Francis; Rohit Varma; Joel S Schuman; David Huang
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

4.  In Vivo Sublayer Analysis of Human Retinal Inner Plexiform Layer Obtained by Visible-Light Optical Coherence Tomography.

Authors:  Zeinab Ghassabi; Roman V Kuranov; Joel S Schuman; Ronald Zambrano; Mengfei Wu; Mengling Liu; Behnam Tayebi; Yuanbo Wang; Ian Rubinoff; Xiaorong Liu; Gadi Wollstein; Hao F Zhang; Hiroshi Ishikawa
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

5.  Focal Loss Analysis of Nerve Fiber Layer Reflectance for Glaucoma Diagnosis.

Authors:  Ou Tan; Liang Liu; Qisheng You; Jie Wang; Aiyin Chen; Eliesa Ing; John C Morrison; Yali Jia; David Huang
Journal:  Transl Vis Sci Technol       Date:  2021-05-03       Impact factor: 3.283

6.  Study of Optimal Perimetric Testing In Children (OPTIC): developing consensus and setting research priorities for perimetry in the management of children with glaucoma.

Authors:  Dipesh E Patel; Phillippa M Cumberland; Bronwen C Walters; Joseph Abbott; John Brookes; Beth Edmunds; Peng Tee Khaw; Ian Christopher Lloyd; Maria Papadopoulos; Velota Sung; Mario Cortina-Borja; Jugnoo S Rahi
Journal:  Eye (Lond)       Date:  2021-06-21       Impact factor: 4.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.